Publications by authors named "I K Mellinghoff"
Importance: Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS) tumors. Yet there remains a great deal of heterogeneity in using such biomarker testing across institutions and hospital systems. This is in large part because there is a persistent reluctance among third-party payers to cover molecular testing.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed genetic alterations in cerebrospinal fluid (CSF) from 711 patients to help classify CNS cancers and guide targeted therapies.
- They found detectable circulating tumor DNA (ctDNA) in over half of CSF samples from patients with CNS tumors, while none was found in samples from patients without CNS tumors.
- The research also revealed clonal evolution and resistance mechanisms over time, with ctDNA presence linked to poorer overall survival rates for these patients.
Purpose: Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity of ibrutinib in 20 patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL).
Patients And Methods: We enrolled 26 additional patients with r/r PCNSL/SCNSL into the dose-expansion cohort of the trial into a combined cohort of 46 patients (31 with PCNSL and 15 with SCNSL).
Purpose: Classic Hodgkin lymphoma (cHL) is a B-cell lymphoma that occurs primarily in young adults and, less frequently, in elderly individuals. A hallmark of cHL is the exceptional scarcity (1%-5%) of the malignant Hodgkin Reed-Sternberg (HRS) cells within a network of nonmalignant immune cells. Molecular determinants governing the relationship between HRS cells and their proximal microenvironment remain largely unknown.
View Article and Find Full Text PDFArticle Synopsis
- * A study tested the feasibility of administering HD-MTX in an outpatient setting with the aid of low-dose glucarpidase to help clear the drug more quickly.
- * Results showed that all treatments were effective and safe, with no hospitalizations needed, suggesting that outpatient HD-MTX with glucarpidase could change how CNS lymphoma is treated.